Home » Federal Court Okays Remicade Biosimilar
Federal Court Okays Remicade Biosimilar
August 2, 2018
A federal court ruled Pfizer can continue to market its biosimilar for Johnson & Johnson’s immunosuppressant drug Remicade (infliximab).
J&J subsidiary Janssen sued Celltrion, the biosimilar’s South Korean manufacturer, and the Pfizer subsidiary Hospira in 2015 over their biosimilar Inflectra, claiming it infringed on a Janssen-owned patent.
On July 30, the U.S. District Court of Massachusetts ruled in favor of Celltrion and Hospira, removing the final legal barrier to the continued marketing of Inflectra.
Upcoming Events
-
21Oct